News
Low Doses of Bevacizumab Tested for Retinopathy of Prematurity
Phase 1 study suggests that intravitreous injection of 0.004mg may be lowest effective dose.
Your search for bevacizumab returned 63 results
News, Oncology
QoL Extended With Atezolizumab + Bevacizumab in Liver Cancer
And, triplet and doublet drug regimens delay decline in quality of life in BRAF V600E metastatic CRC.
News
Adding Bevacizumab May Improve Overall Survival in NSCLC
Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non-small cell lung cancer
News
Intravitreal Anti-VEGF Use Not Tied to Systemic Adverse Events
In the most recent and exhaustive reviews, bevacizumab was not associated with an increase in the risk of systemic adverse events compared with ranibizumab. In patients with age-related macular degeneration, ranibizumab may be associated with increased risk of nonocular hemorrhage compared with control treatments.
News
Atezolizumab + Bevacizumab vs. Sunitinib in Met Renal CA
The researchers found that the hazard ratio for progression-free survival was 0.74 and 0.83 for atezolizimab plus bevacizumab versus sunitinib in PD-L1+ patients and intention-to-treat patients, respectively.
News
Results Released in Multi-Year IV Bevacizumab Study for HHT-Related Bleeding
After completion of the initial bevacizumab treatment cycle, there was a significant reduction in epistaxis severity scores and RBC transfusion requirements.
News
Prevalence of Persistent DME Evaluated After Anti-VEGF Therapy
Persistent diabetic macular edema more likely with bevacizumab than aflibercept or ranibizumab
News
Survival With Combo Bevacizumab + Lomustine Tx Examined in Glioblastoma
However, locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group.
News
Anti-VEGF Treatments Examined for Effects on Diabetic Retinopathy
Researchers conducted a secondary analysis of data from a comparative effectiveness trial for center-involved DME in 650 participants during 2 years of treatment with aflibercept (2mg), bevacizumab (1.25mg), or ranibizumab (0.3mg).
News
Antibiotics May Negatively Impact Patients on Certain Cancer Drugs
Progression-free survival down with antibiotic use for patients receiving immune checkpoint inhibitors
